July 9, 2018 05:28 PM EDT

A 7-year-old alliance between Celgene and Acceleron is paying off with more promising PhIII data for luspatercept

Just days after hitting its first set of marks in a critically important Phase III study, Acceleron $XLRN and its partners at Celgene $CELG say …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A 7-year-old al­liance be­tween Cel­gene and Ac­celeron is pay­ing off with more promis­ing PhI­II da­ta for lus­pa­ter­cept